A new global systematic review suggests that the shingles vaccine could reduce the risk of cardiovascular events. Analyzing 19 studies, researchers found that adults who received the vaccine had an 18% lower risk of stroke or heart attack, with a 16% reduction in adults over 50.
The findings, presented at the European Society of Cardiology congress in Madrid, indicate that vaccination may offer benefits beyond infection prevention. Experts note that preventing shingles could reduce inflammation in the body, which plays a key role in heart and circulatory conditions.
While the vaccine is currently recommended mainly for older or immunocompromised adults, the results suggest potential benefits for younger adults as well. Further research is needed to confirm these protective effects and to explore the underlying mechanisms.
The NHS is expanding eligibility from September, allowing 300,000 more people, including adults aged 18–49 with weakened immune systems, to receive the shingles jab.
